AAPL319.97-8.24 (-2.51%) ▼|ABBV256.46-3.75 (-1.44%) ▼|ABT107.40-0.91 (-0.84%) ▼|ACN180.14-6.56 (-3.51%) ▼|ADBE259.44-7.07 (-2.65%) ▼|AMAT469.15+14.44 (+3.18%) ▲|AMD491.64+14.07 (+2.95%) ▲|AMGN403.23-34.00 (-7.78%) ▼|AMT175.47-0.28 (-0.16%) ▼|AMZN255.62-2.90 (-1.12%) ▼|AVGO366.80+8.91 (+2.49%) ▲|AXP322.83-3.26 (-1.00%) ▼|BA211.71-0.52 (-0.24%) ▼|BAC62.36-0.33 (-0.52%) ▼|BKNG187.95-5.34 (-2.76%) ▼|BLK1,107.63-8.47 (-0.76%) ▼|BMY64.75-2.09 (-3.12%) ▼|BNY163.27-1.58 (-0.96%) ▼|BRK-B501.63-4.27 (-0.84%) ▼|C136.21-1.53 (-1.11%) ▼|CAT820.33+6.47 (+0.80%) ▲|CL88.13-0.63 (-0.71%) ▼|CMCSA26.23-0.27 (-1.00%) ▼|COF216.53-3.02 (-1.38%) ▼|COP136.05+1.76 (+1.31%) ▲|COST911.37-4.38 (-0.48%) ▼|CRM251.78-7.52 (-2.90%) ▼|CSCO109.01-0.19 (-0.17%) ▼|CVS95.50-1.25 (-1.29%) ▼|CVX211.96+3.43 (+1.64%) ▲|DE687.04-6.64 (-0.96%) ▼|DHR205.38-2.24 (-1.08%) ▼|DIS104.81-0.48 (-0.46%) ▼|DUK120.54+0.32 (+0.26%) ▲|EMR152.72-0.08 (-0.05%) ▼|FDX320.49-1.88 (-0.58%) ▼|GD359.99+0.60 (+0.17%) ▲|GE335.79-1.24 (-0.37%) ▼|GEV947.49+5.57 (+0.59%) ▲|GILD146.58-4.42 (-2.92%) ▼|GM87.23-0.51 (-0.58%) ▼|GOOG332.40-2.92 (-0.87%) ▼|GOOGL335.77-2.69 (-0.79%) ▼|GS1,033.62-4.68 (-0.45%) ▼|HD320.32-0.68 (-0.21%) ▼|HON208.32-1.29 (-0.62%) ▼|IBM231.56-3.28 (-1.40%) ▼|INTC101.68+5.88 (+6.14%) ▲|INTU321.32-11.38 (-3.42%) ▼|ISRG358.51-8.19 (-2.23%) ▼|JNJ268.32-6.83 (-2.48%) ▼|JPM357.00-1.62 (-0.45%) ▼|KO88.24+0.17 (+0.19%) ▲|LIN472.33-5.25 (-1.10%) ▼|LLY1,116.00-32.74 (-2.85%) ▼|LMT536.40+11.24 (+2.14%) ▲|LOW204.33-0.24 (-0.12%) ▼|LRCX316.43+8.78 (+2.85%) ▲|MA570.32-8.85 (-1.53%) ▼|MCD255.15-0.57 (-0.22%) ▼|MDLZ61.37+0.09 (+0.15%) ▲|MDT92.35-1.81 (-1.92%) ▼|META617.88+1.11 (+0.18%) ▲|MMM168.03-0.48 (-0.28%) ▼|MO68.94+0.07 (+0.10%) ▲|MRK146.57-3.76 (-2.50%) ▼|MS217.40-0.31 (-0.14%) ▼|MSFT494.03-5.67 (-1.13%) ▼|MU1,016.88+0.29 (+0.03%) ▲|NEE83.64+0.22 (+0.26%) ▲|NFLX76.53-1.73 (-2.20%) ▼|NKE38.47+0.06 (+0.14%) ▲|NOW135.36-5.91 (-4.18%) ▼|NVDA232.54+2.18 (+0.95%) ▲|ORCL169.32+10.49 (+6.60%) ▲|PEP138.17+0.54 (+0.39%) ▲|PFE27.80-0.65 (-2.27%) ▼|PG145.43-1.02 (-0.70%) ▼|PLTR174.60+0.27 (+0.15%) ▲|PM185.36+2.85 (+1.56%) ▲|QCOM179.87+11.13 (+6.59%) ▲|RTX199.98-0.81 (-0.40%) ▼|SBUX103.69-0.79 (-0.75%) ▼|SCHW109.24-0.05 (-0.05%) ▼|SO88.49+0.37 (+0.42%) ▲|SPG208.40-0.92 (-0.44%) ▼|T25.73+0.06 (+0.23%) ▲|TMO606.80-6.95 (-1.13%) ▼|TMUS182.45+0.93 (+0.51%) ▲|TSLA361.55+7.47 (+2.11%) ▲|TXN259.58+1.14 (+0.44%) ▲|UBER73.67-2.11 (-2.78%) ▼|UNH394.29-2.81 (-0.71%) ▼|UNP288.87-0.75 (-0.26%) ▼|UPS101.61-0.68 (-0.66%) ▼|USB62.97-0.40 (-0.62%) ▼|V371.17-3.81 (-1.01%) ▼|VZ50.32+0.19 (+0.37%) ▲|WFC89.02-0.92 (-1.02%) ▼|WMT106.22-0.92 (-0.86%) ▼|XOM162.07+2.61 (+1.64%) ▲|AAPL319.97-8.24 (-2.51%) ▼|ABBV256.46-3.75 (-1.44%) ▼|ABT107.40-0.91 (-0.84%) ▼|ACN180.14-6.56 (-3.51%) ▼|ADBE259.44-7.07 (-2.65%) ▼|AMAT469.15+14.44 (+3.18%) ▲|AMD491.64+14.07 (+2.95%) ▲|AMGN403.23-34.00 (-7.78%) ▼|AMT175.47-0.28 (-0.16%) ▼|AMZN255.62-2.90 (-1.12%) ▼|AVGO366.80+8.91 (+2.49%) ▲|AXP322.83-3.26 (-1.00%) ▼|BA211.71-0.52 (-0.24%) ▼|BAC62.36-0.33 (-0.52%) ▼|BKNG187.95-5.34 (-2.76%) ▼|BLK1,107.63-8.47 (-0.76%) ▼|BMY64.75-2.09 (-3.12%) ▼|BNY163.27-1.58 (-0.96%) ▼|BRK-B501.63-4.27 (-0.84%) ▼|C136.21-1.53 (-1.11%) ▼|CAT820.33+6.47 (+0.80%) ▲|CL88.13-0.63 (-0.71%) ▼|CMCSA26.23-0.27 (-1.00%) ▼|COF216.53-3.02 (-1.38%) ▼|COP136.05+1.76 (+1.31%) ▲|COST911.37-4.38 (-0.48%) ▼|CRM251.78-7.52 (-2.90%) ▼|CSCO109.01-0.19 (-0.17%) ▼|CVS95.50-1.25 (-1.29%) ▼|CVX211.96+3.43 (+1.64%) ▲|DE687.04-6.64 (-0.96%) ▼|DHR205.38-2.24 (-1.08%) ▼|DIS104.81-0.48 (-0.46%) ▼|DUK120.54+0.32 (+0.26%) ▲|EMR152.72-0.08 (-0.05%) ▼|FDX320.49-1.88 (-0.58%) ▼|GD359.99+0.60 (+0.17%) ▲|GE335.79-1.24 (-0.37%) ▼|GEV947.49+5.57 (+0.59%) ▲|GILD146.58-4.42 (-2.92%) ▼|GM87.23-0.51 (-0.58%) ▼|GOOG332.40-2.92 (-0.87%) ▼|GOOGL335.77-2.69 (-0.79%) ▼|GS1,033.62-4.68 (-0.45%) ▼|HD320.32-0.68 (-0.21%) ▼|HON208.32-1.29 (-0.62%) ▼|IBM231.56-3.28 (-1.40%) ▼|INTC101.68+5.88 (+6.14%) ▲|INTU321.32-11.38 (-3.42%) ▼|ISRG358.51-8.19 (-2.23%) ▼|JNJ268.32-6.83 (-2.48%) ▼|JPM357.00-1.62 (-0.45%) ▼|KO88.24+0.17 (+0.19%) ▲|LIN472.33-5.25 (-1.10%) ▼|LLY1,116.00-32.74 (-2.85%) ▼|LMT536.40+11.24 (+2.14%) ▲|LOW204.33-0.24 (-0.12%) ▼|LRCX316.43+8.78 (+2.85%) ▲|MA570.32-8.85 (-1.53%) ▼|MCD255.15-0.57 (-0.22%) ▼|MDLZ61.37+0.09 (+0.15%) ▲|MDT92.35-1.81 (-1.92%) ▼|META617.88+1.11 (+0.18%) ▲|MMM168.03-0.48 (-0.28%) ▼|MO68.94+0.07 (+0.10%) ▲|MRK146.57-3.76 (-2.50%) ▼|MS217.40-0.31 (-0.14%) ▼|MSFT494.03-5.67 (-1.13%) ▼|MU1,016.88+0.29 (+0.03%) ▲|NEE83.64+0.22 (+0.26%) ▲|NFLX76.53-1.73 (-2.20%) ▼|NKE38.47+0.06 (+0.14%) ▲|NOW135.36-5.91 (-4.18%) ▼|NVDA232.54+2.18 (+0.95%) ▲|ORCL169.32+10.49 (+6.60%) ▲|PEP138.17+0.54 (+0.39%) ▲|PFE27.80-0.65 (-2.27%) ▼|PG145.43-1.02 (-0.70%) ▼|PLTR174.60+0.27 (+0.15%) ▲|PM185.36+2.85 (+1.56%) ▲|QCOM179.87+11.13 (+6.59%) ▲|RTX199.98-0.81 (-0.40%) ▼|SBUX103.69-0.79 (-0.75%) ▼|SCHW109.24-0.05 (-0.05%) ▼|SO88.49+0.37 (+0.42%) ▲|SPG208.40-0.92 (-0.44%) ▼|T25.73+0.06 (+0.23%) ▲|TMO606.80-6.95 (-1.13%) ▼|TMUS182.45+0.93 (+0.51%) ▲|TSLA361.55+7.47 (+2.11%) ▲|TXN259.58+1.14 (+0.44%) ▲|UBER73.67-2.11 (-2.78%) ▼|UNH394.29-2.81 (-0.71%) ▼|UNP288.87-0.75 (-0.26%) ▼|UPS101.61-0.68 (-0.66%) ▼|USB62.97-0.40 (-0.62%) ▼|V371.17-3.81 (-1.01%) ▼|VZ50.32+0.19 (+0.37%) ▲|WFC89.02-0.92 (-1.02%) ▼|WMT106.22-0.92 (-0.86%) ▼|XOM162.07+2.61 (+1.64%) ▲|
20 C
New York
Tuesday, September 8, 2026

Tag: biotech company

newssourceFORcompanyinformationcontent1releasesmarket

ArkBio’s New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA

SHANGHAI, June 15, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the National Medical Products Administration (NMPA) has officially accepted...

Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics

Vancouver, Canada, June 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics

BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer

MAINZ and TÜBINGEN, Germany, June 12, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a clinical-stage biotech company developing a novel class of transformative medicines in oncology and infectious diseases based on messenger ribonucleic acid (“mRNA”). The all-stock transaction will bring together two highly complementary companies based in Germany and will build on BioNTech’s proven track record and established position in the global mRNA industry.

Fapon Biopharma to Showcase Differentiated Pipeline, Including Phase 1 Immunocytokine FP008, and Innovative Technology Platforms at BIO 2025

BOSTON, June 12, 2025 /PRNewswire/ -- Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce its participation...

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors

Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement that was carried out on June 4, 2025, directed to Swedish and international institutional investors. About 40 institutional investors participated in the placement. About 60% of the demand came from institutional investors based in Sweden, Norway or the UK, and about 30% from US-based funds. Over 80% of the shares and Swedish Depositary Receipts (SDRs) allocated in the placement, were sold to investors that were not previously shareholders in Alvotech.

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors

Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement that was carried out on June 4, 2025, directed to Swedish and international institutional investors. About 40 institutional investors participated in the placement. About 60% of the demand came from institutional investors based in Sweden, Norway or the UK, and about 30% from US-based funds. Over 80% of the shares and Swedish Depositary Receipts (SDRs) allocated in the placement, were sold to investors that were not previously shareholders in Alvotech.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBiotech company

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers